scholarly journals Clinical and Immunological Features of Human Leishmania (L.) infantum-Infection, Novel Insights Honduras, Central America

Pathogens ◽  
2020 ◽  
Vol 9 (7) ◽  
pp. 554
Author(s):  
Wilfredo Sosa-Ochoa ◽  
Concepción Zúniga ◽  
Luis Fernando Chaves ◽  
Gabriela Venicia Araujo Flores ◽  
Carmen Maria Sandoval Pacheco ◽  
...  

Leishmania (Leishmania) infantum is the etiological agent of both American visceral leishmaniasis (AVL) and non-ulcerated cutaneous leishmaniasis (NUCL) in Honduras. Although AVL is the most severe clinical form of infection, recent studies have shown that human immune response to parasite infection can result in a clinical-immunological spectrum. The overall prevalence rate of infection and clinical-immunological profiles of the L. (L.) infantum infection in Amapala municipality, South Honduras was determined. We examined 576 individuals with diagnosis based on combined ELISA (IgG/IgM) and DTH assays. We also used genus-specific kDNA PCR and Hsp70 PCR-RFLP for NUCL cases. Clinical evaluation found 82% asymptomatic and 18% symptomatic individuals. All symptomatic cases (n = 104) showing NUCL were positive for parasites. We identified L. (L.) infantum species in 100% of the skin lesion scrapings and in 90% of the blood samples from NUCL cases studied. A total of 320 asymptomatic individuals were exposed (ELISA+ and/or DTH+), providing an overall L. (L.) infantum prevalence of 73.6%. Clinical, parasitological, and immunological evaluations suggest seven infection profiles, three asymptomatic and four symptomatic. This represents the first report on clinical and immunological features of human L. (L.) infantum-infection in Amapala municipality, Honduras.


2021 ◽  
Vol 27 (4) ◽  
pp. 571-572 ◽  
Author(s):  
Roberto Burioni ◽  
Eric J. Topol


2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Diane Williamson

This review considers the steps required to evaluate a candidate biodefense vaccine or therapy as it emerges from the research phase, in order to transition it to development. The options for preclinical modelling of efficacy are considered in the context of the FDA’s Animal Rule.





1989 ◽  
Vol 21 (4) ◽  
pp. 386???392 ◽  
Author(s):  
LEONARD H. CALABRESE ◽  
SUSAN M. KLEINER ◽  
BARBARA P. BARNA ◽  
CHRISTINE I. SKIBINSKI ◽  
DONALD T. KIRKENDALL ◽  
...  




2007 ◽  
Vol 1004 ◽  
Author(s):  
David B. Fenner ◽  
David I Rosen ◽  
Anthony A Ferrante ◽  
Amy E Stevens ◽  
Chad E Bigelow ◽  
...  

AbstractDevelopment of field portable apparatus and methods for cytokine assay of human saliva by fluorescent-reporting microarray plates is described. Multiplexed assay of 12 cytokines for minimally-processed saliva is read with a CCD-based imager under LED excitation. Immune responsive cytokines are measured at levels significant for indication of human disease state. The motivational context for the new apparatus development, the general optical design issues, saliva protocol, and image analysis are described.



Hybridoma ◽  
1999 ◽  
Vol 18 (2) ◽  
pp. 121-129 ◽  
Author(s):  
WENDY A. HUTCHINS ◽  
THOMAS KIEBER-EMMONS ◽  
GEORGE M. CARLONE ◽  
M.A. JULIE WESTERINK


Author(s):  
Silvia Castellanos-Castro ◽  
Arturo Aguilar-Rojas ◽  
Mariette Matondo ◽  
Quentin Gian Gianetto ◽  
Hugo Varet ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document